{"analyses":[{"ciLowerLimit":"-5.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"11.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.7","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on global response.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.78","paramType":"Mean Difference (Final Values)","paramValue":"3.1","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-4.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.7","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.5","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on global response.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.75","paramType":"Mean Difference (Final Values)","paramValue":"3.0","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-0.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.7","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.3","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on global response.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.08","paramType":"Mean Difference (Final Values)","paramValue":"6.6","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-1.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.4","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on global response.","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.17","paramType":"Mean Difference (Final Values)","paramValue":"5.8","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-6.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.7","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on High Initial NFkB Activation Expressers.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.61","paramType":"Mean Difference (Final Values)","paramValue":"5.3","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-4.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.8","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.1","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on High Initial NFkB Activation Expressers.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.32","paramType":"Mean Difference (Final Values)","paramValue":"6.3","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"1.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.8","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on High Initial NFkB Activation Expressers.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.03","paramType":"Mean Difference (Final Values)","paramValue":"12.0","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"0.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.8","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.1","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on High Initial NFkB Activation Expressers.","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.04","paramType":"Mean Difference (Final Values)","paramValue":"11.1","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-1.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.4","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on Low Initial NFkB Activation Expressers.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.00","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-3.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.7","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on Low Initial NFkB Activation Expressers.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.88","paramType":"Mean Difference (Final Values)","paramValue":"-0.6","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-0.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.3","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on Low Initial NFkB Activation Expressers.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.98","paramType":"Mean Difference (Final Values)","paramValue":"0.1","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false},{"ciLowerLimit":"-6.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.2","groupDescription":"Omnibus analysis. Statistical significance was determined by Games Howell Multiple Comparison test. Significance was determined as α\\< 0.05.\n\nAnalysis based on Low Initial NFkB Activation Expressers.","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.98","paramType":"Mean Difference (Final Values)","paramValue":"-0.6","statisticalComment":"Games-Howell Correction was applied to adjust for unequal variances, unequal sample size and for non-parametric distribution.","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.945","spread":"2.25","upperLimit":"231","value":"7.2"},{"groupId":"OG001","spread":"1.53","value":"4.1"},{"groupId":"OG002","spread":"1.15","value":"4.2"},{"groupId":"OG003","spread":"0.94","value":"0.7"},{"groupId":"OG004","spread":"0.86","value":"1.5"}]}],"title":"Total Population"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.77","value":"12.8"},{"groupId":"OG001","spread":"2.41","value":"7.4"},{"groupId":"OG002","spread":"1.42","value":"6.4"},{"groupId":"OG003","spread":"0.20","value":"0.8"},{"groupId":"OG004","spread":"1.44","value":"1.6"}]}],"title":"Higher Initial Expressers"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.27","value":"0.8"},{"groupId":"OG001","spread":"0.37","value":"0.9"},{"groupId":"OG002","spread":"0.80","value":"1.5"},{"groupId":"OG003","spread":"0.11","value":"0.6"},{"groupId":"OG004","spread":"1.16","value":"1.3"}]}],"title":"Lower Initial Expressers"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Peripheral lymphocytes were isolated from the blood using Ficoll-Paque gradient. Nuclear Factor Kappa B activation was analyzed using Thermo Scientific Transcription Factor kit for NFkB p50, according to manufacturer's protocol. Protein extracts containing 1-15µg of protein/well were added in triplicates. Luminescence resulting from a reaction with bound NFkB was detected using a Berthold Centro LB960 Luminometer and analyzed with MikroWin 2000 ver. 1.08. NFkB activity was normalized by luminescence units/µg of protein per well.","dispersionType":"Standard Error","groups":[{"description":"Baseline nuclear factor Kappa B (NFkB) activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia.","id":"OG000","title":"Baseline Nuclear Factor Kappa B Activation"},{"description":"Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 3 capsules per day (2.4 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.","id":"OG001","title":"Nuclear Factor Kappa B Activation Following 3 Capsules Per Day"},{"description":"Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 6 capsules per day (4.8 g of omega 3 per day).Each 1250mg capsule provided 800mg of omega 3.","id":"OG002","title":"Nuclear Factor Kappa B Activation Following 6 Capsules Per Day"},{"description":"Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following consumption of 9 capsules per day (7.2 g of omega 3 per day). Each 1250mg capsule provided 800mg of omega 3.","id":"OG003","title":"Nuclear Factor Kappa B Activation Following 9 Capsules Per Day"},{"description":"Nuclear factor Kappa B (NFkB)activation in isolated lymphocytes from patients with early stage chronic lymphocytic leukemia following discontinued consumption of omega 3.","id":"OG004","title":"Nuclear Factor Kappa B Activation Post Supplement"}],"paramType":"MEAN","populationDescription":"NFkB activation of all patients diagnosed with early stage CLL at baseline and following omega 3 consumption. Patients are further separated into high (\\> median, n=7) and low initial baseline (\\< median, n=6) NFkB. Patients included must have had one baseline and at least one period of omega 3 consumption. Not all patients completed all periods","reportingStatus":"POSTED","timeFrame":"baseline, and post supplement month 1(3 capsules/day), month 2 (6capsules/day), month 3 (9 capusules/day), month 6 (9 capusules/day), month 9 (9 capusules/day), month 12 (post supplement)","title":"Activated Nuclear Factor Kappa B (NFkB) in Peripheral Blood Lymphocytes From Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) Before, During and After Consumption of an Omega 3 Supplement.","type":"PRIMARY","unitOfMeasure":"10^6 NFkB Luminescence units/µg protein"}